Nicholas Nissen
Overview
Explore the profile of Nicholas Nissen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
793
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Huang H, Nissen N, Lim C, Goren J, Spottswood M, Huang H
Int J Gen Med
. 2022 Nov;
15:8299-8314.
PMID: 36447648
Bipolar disorder is a chronic mental illness associated with early mortality, elevated risk of comorbid cardiovascular disease, enormous burden of disability, and large societal costs. Patients often seek treatment for...
12.
Chen L, Davelaar J, Gaddam S, Kosari K, Nissen N, Chaux G, et al.
J Natl Compr Canc Netw
. 2022 Nov;
21(1):6-11.
PMID: 36395704
Pancreatic metastasis of primary lung adenocarcinoma is a rare occurrence, accounting for <0.3% of all pancreatic malignancies. Given that the prognosis and treatment options for primary pancreatic cancer differ greatly...
13.
Park K, Rosas U, Liu Q, Jamil L, Gupta K, Gaddam S, et al.
Endosc Int Open
. 2022 Aug;
10(8):E1088-E1094.
PMID: 35979034
No abstract available.
14.
Ahn J, Lauzon M, Luu M, Noureddin M, Ayoub W, Kuo A, et al.
Hepatology
. 2022 Apr;
76(6):1649-1659.
PMID: 35429171
Background And Aims: Immunotherapy has emerged as an effective treatment for patients with advanced-stage HCC. We aimed to investigate the efficacy of immunotherapy for advanced HCC in a nationwide cohort...
15.
Tuli R, Lo S, Koo J, Pishvaian M, Bender R, Petricoin E, et al.
JCO Precis Oncol
. 2022 Feb;
1:1-5.
PMID: 35172502
No abstract available.
16.
Klempner S, Hendifar A, Waters K, Nissen N, Vail E, Tuli R, et al.
JCO Precis Oncol
. 2022 Jan;
4:614-619.
PMID: 35050748
No abstract available.
17.
Govalan R, Lauzon M, Luu M, Ahn J, Kosari K, Todo T, et al.
Liver Cancer
. 2021 Nov;
10(5):407-418.
PMID: 34721504
Introduction: Small studies from outside of the USA suggest excellent outcomes after surgical resection for hepatocellular carcinoma (HCC) with vascular invasion. The study aims to (1) compare overall survival after...
18.
Placencio-Hickok V, Lauzon M, Moshayedi N, Guan M, Kim S, Nissen N, et al.
Pancreatology
. 2021 Oct;
22(1):92-97.
PMID: 34657790
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers with poor survival. The dense desmoplastic stroma in PDAC contributes to treatment resistance. Among the components comprising the...
19.
Gresham G, Placencio-Hickok V, Lauzon M, Nguyen T, Kim H, Mehta S, et al.
J Cachexia Sarcopenia Muscle
. 2021 Oct;
12(6):1959-1968.
PMID: 34609081
Background: Advanced pancreatic ductal adenocarcinoma (PDAC) is characterized by progressive weight loss and nutritional deterioration. This wasting has been linked to poor survival outcomes, alterations in host defenses, decreased functional...
20.
Govalan R, Luu M, Lauzon M, Kosari K, Ahn J, Rich N, et al.
Hepatol Commun
. 2021 Sep;
6(1):223-236.
PMID: 34558830
Prognosis of hepatocellular carcinoma (HCC) could be affected by lack of or delayed therapy. We aimed to characterize the prevalence, correlates, and clinical impact of therapeutic underuse and delay in...